Elicio Therapeutics, Inc. announced on August 12, 2025, the publication of follow-up data from its Phase 1 AMPLIFY-201 study in the peer-reviewed scientific journal, Nature Medicine. The article, titled 'Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: Phase 1 AMPLIFY-201 trial final results,' highlights extended follow-up data.
The published data revealed that more than two-thirds of participants, specifically 17 of 25, whose T cell responses exceeded the antitumor efficacy threshold, experienced a significantly reduced risk for relapse or death. This finding further strengthens the belief in the Amphiphile (AMP) platform as a potentially transformative approach for mKRAS-driven tumors.
The updated Phase 1 AMPLIFY-201 data demonstrate the AMP platform's potential to provide durable benefit to pancreatic ductal adenocarcinoma (PDAC) patients in the adjuvant setting. This publication, combined with the recent positive recommendation from the IDMC for the AMPLIFY-7P study, represents critical advancements for the ELI-002 program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.